Due to the ongoing 2019 Coronavirus disease (COVID-19) outbreak, UCAncer (initially planned June 15-16, then November 16-17, 2020) has been postponed to October 25-26 2021
Cancer is a complex group of diseases challenging science and medicine. Over the years, it has become evident that an integrated approach encompassing traditional disciplines such as biology, data science and statistics, computer science, applied mathematics, physics, chemistry, physio-pathology and medicine was mandatory to understand and classify cancers, and envision effective treatments.
The Symposium “Multidisciplinary Approaches in Cancer Research” perfectly illustrates this perspective, as the two day program features leading experts from the aforementioned disciplines, whose keynote lectures will cover the following themes:
Session 1: Chemical biology for cancer therapy
Session 2: Personalized and translational medicine
Session 3: Mathematical models of tumor growth
Session 4: Network and systems biology of cancer
Session 5: Response to cancer treatment
Session 6: Industrial transfer: local success stories
A health pass will be mandatory to access UCAncer event.
France has made it obligatory to show a passe sanitaire (health pass) – proving that you are vaccinated or have tested negative for Covid-19 – for access to events venues.
Any of the following documents can be used as a health pass in France:
- Proof of having completed a vaccination programme (two doses of an EU-approved vaccine: Pfizer, Moderna, AstraZeneca or Johnson & Johnson)
- A negative PCR or antigen test taken within the last 72 hours
- A Covid-19 recovery certificate that is less than six months old
Passes can be digital (on the TousAntiCovid app) or in paper form (proof of vaccination or test result). They include a QR code that will be scanned on entry into the venue or event.
The French health pass is interoperable with the EU Digital COVID Certificate scheme for travel within the European Union, Iceland, Lichtenstein, Norway, San Marino, Switzerland and the Vatican.
